Myeloid leukemia

Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab

Retrieved on: 
Thursday, March 14, 2024
Nasdaq First North, AML, Fårö, Associate, Webcast, Patient, Myeloid leukemia, Standard of care, Acute myeloid leukemia, University, Doctor of Philosophy, MD, Myelodysplastic syndrome, Faron Pharmaceuticals, Myelocyte, MDS, AIM

This interactive event will also include an introduction to myeloid leukemia, insights into bexmarilimab’s unique mode of action and the Company’s latest understanding of the early and long-term efficacy of bexmarilimab treatment.

Key Points: 
  • This interactive event will also include an introduction to myeloid leukemia, insights into bexmarilimab’s unique mode of action and the Company’s latest understanding of the early and long-term efficacy of bexmarilimab treatment.
  • Faron will also provide an update on bexmarilimab’s future development pathway and business opportunity.
  • There will be an opportunity to ask questions during the webcast.
  • To register for the event visit: https://faron.videosync.fi/bexmab-study-update/ or contact the IR team for more information at [email protected] .

Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets

Retrieved on: 
Tuesday, March 5, 2024
Trichloroethylene, Therapy, CG1, Doctor of Philosophy, TCE, MD, Immunotherapy, Monroe Dunaway Anderson, AACR, Cathepsin G, Annual general meeting, Safety, MD Anderson Cancer Center, University, Mass spectrometry, Myeloid leukemia, TCR, Malignancy, CTSG, Cancer, Pharmaceutical industry

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Crossbow Therapeutics, Inc., a biotechnology company focused on advancing T-Bolt™ therapies, a novel class of antibody therapeutics that mimic T-cell receptors (TCR-mimetics), today announced the nomination of its first development candidate, CBX-250, a first-in-class, potent, and specific T-cell engager (TCE) for the treatment of myeloid leukemia.

Key Points: 
  • The oral presentation will provide an overview of the preclinical characteristics of CBX-250, which targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex.
  • The complex is abundantly expressed on leukemic cells, but not on normal cells, allowing CBX-250 to target cancer cells efficiently while sparing normal myeloid cells.
  • “Nominating CBX-250 as a development candidate validates our initial scientific hypothesis, and it brings us a step closer to entering the clinic and ultimately helping to cure cancer,” said Briggs Morrison, Chief Executive Officer of Crossbow.
  • Working with MD Anderson’s ORBIT platform, a core component of the institution’s Therapeutics Discovery division , Dr. Molldrem led the development of a TCR-mimetic binder to the CG1 pHLA complex, which Crossbow licensed for the development of off-the-shelf cancer immunotherapies.

Therapeutic Vaccines Market Size and Share to Surpass USD 87 Billion by 2035 - Exclusive Report by Roots Analysis

Retrieved on: 
Tuesday, January 9, 2024
Neurological disorder, Patient, Therapy, Research, Cancer, Glioblastoma, ALS, DNA, Epidemic, Tuberculosis, VB, Myeloid leukemia, Lung cancer, Bill, Fever Dream, Infection, Hepatocellular carcinoma, Immune system, Combination therapy, Epstein–Barr virus, Cervical cancer, California Institute of Technology, Intrathecal administration, HIV, Complex, Malaria, Organization, Merck, Vaccine, Colorectal cancer, OPKO Health, Roche, Anal cancer, Prevalence, Growth, Pharmaceutical industry

LONDON, Jan. 9, 2024 /PRNewswire/ -- The global therapeutic vaccines market is estimated to be worth USD 2 billion in 2023 and is anticipated to reach USD 87 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 35% during the forecast period from 2023 to 2035.

Key Points: 
  • The therapeutic vaccines market is also driven by the expanding pipeline of therapeutic vaccine candidates in the clinical development stages.
  • Based on the type of vaccine, the therapeutic vaccines market is segmented into antigen vaccines, dendritic vaccines, DNA vaccines, and peptide vaccines.
  • Based on the type of method of vaccine composition, the therapeutic vaccines market is segmented into autologous vaccines, allogeneic vaccines and other methods.
  • Europe will dominate the therapeutic vaccines market and is anticipated to capture 59% of the overall revenue share in 2023.

Therapeutic Vaccines Market Size and Share to Surpass USD 87 Billion by 2035 - Exclusive Report by Roots Analysis

Retrieved on: 
Tuesday, January 9, 2024
Neurological disorder, Patient, Therapy, Research, Cancer, Glioblastoma, ALS, DNA, Epidemic, Tuberculosis, VB, Myeloid leukemia, Lung cancer, Bill, Fever Dream, Infection, Hepatocellular carcinoma, Immune system, Combination therapy, Epstein–Barr virus, Cervical cancer, California Institute of Technology, Intrathecal administration, HIV, Complex, Malaria, Organization, Merck, Vaccine, Colorectal cancer, OPKO Health, Roche, Anal cancer, Prevalence, Growth, Pharmaceutical industry

LONDON, Jan. 9, 2024 /PRNewswire/ -- The global therapeutic vaccines market is estimated to be worth USD 2 billion in 2023 and is anticipated to reach USD 87 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 35% during the forecast period from 2023 to 2035.

Key Points: 
  • The therapeutic vaccines market is also driven by the expanding pipeline of therapeutic vaccine candidates in the clinical development stages.
  • Based on the type of vaccine, the therapeutic vaccines market is segmented into antigen vaccines, dendritic vaccines, DNA vaccines, and peptide vaccines.
  • Based on the type of method of vaccine composition, the therapeutic vaccines market is segmented into autologous vaccines, allogeneic vaccines and other methods.
  • Europe will dominate the therapeutic vaccines market and is anticipated to capture 59% of the overall revenue share in 2023.

Global BCR ABL Tyrosine Kinase Inhibitor Drug Market Report 2023: Clinical Insight On Approved BCR ABL Inhibitors Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, July 10, 2023
Pharmaceutical, Health, Clinical Trials, Asciminib, CML, BCR, Mutation, BCR-ABL, Acute leukemia, Bristol Myers Squibb, Sale, Myeloid leukemia, Name, Novartis, Patient, Patent, Dasatinib, Leukemia, Pharmaceutical industry, Imatinib, Bayer, Pfizer

Global BCR ABL Inhibitor Drug Market Opportunity: > USD 8 Billion

Key Points: 
  • Global BCR ABL Inhibitor Drug Market Opportunity: > USD 8 Billion
    BCR ABL Inhibitors Drugs Clinical Trials By Company, Indication, and Phase: > 20 Drugs
    Clinical Insight On Approved BCR ABL Inhibitors Drugs: 10 Drugs
    BCR ABL inhibitors have transformed the treatment landscape for patients of chronic myeloid leukemia (CML).
  • Imatinib was the first BCR ABL inhibitor to be approved for the treatment of chronic myeloid leukemia, and as a first-generation inhibitor, its clinical and commercial success led to the development of more efficient BCR ABL inhibitors.
  • However, with the presence of other BCR ABL inhibitors in the market and more in the pipelines, sales of BCR ABL inhibitors are expected to dominate over generic drugs' sales.
  • Scemblix (Asciminib) was the most recent BCR ABL inhibitor to be approved for sale in the market for the treatment of BCR ABL mutation-positive chronic myeloid leukemia and patients having the T315I mutation.

Michael F. Price Memorial Grant from DeGregorio Family Foundation Awarded to Improve Survival Rates in Esophageal Cancer

Retrieved on: 
Tuesday, March 7, 2023
MD, Mitochondrion, Esophageal cancer, Therapy, Cell death, Patient, Research, De Gregorio, Baylor University, Stomach cancer, Grant, Cancer, Baylor College of Medicine, Apoptosis, Myeloid leukemia, Neoplasm, Live-cell imaging, Knowledge, Doctor of Philosophy, BH3, Associate, Pharmaceutical industry, Vaccine

The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.

Key Points: 
  • The Grant is named in memory of Michael F. Price, the noted value investor and philanthropist, who was an early supporter of the Foundation.
  • The ultimate goal is to rapidly determine the best approach for treating each individual patient with esophageal cancer.
  • The DeGregorio Family Foundation, founded in 2006 after a 10th member of the DeGregorio family died of stomach cancer, has raised almost $8 million to fund innovative research focused on curing gastroesophageal cancers.
  • "Esophageal adenocarcinoma is the most common subtype of esophageal cancer in the U.S., and it is one of the fastest-growing cancers today," concluded Lynn DeGregorio, President and Founder.

Pusan National University Researchers Uncover Novel Gene That Regulates Leukemia Development and Progression

Retrieved on: 
Wednesday, February 1, 2023
B cell, AML, Mouse, Bone marrow, Hematological Cancer Research Investment and Education Act, Protein, Myeloid leukemia, Leukemia, ROS, Acute myeloid leukemia, Patient, Aptamer, Cell, RNA, SURF4, Research, Letter, TBK1, Cell death, STAT6, Immune system, Death, Differentiable function, Disease, Growth, Prevalence, Pusan National University, Neoplasm, Vaccine

BUSAN, South Korea, Feb. 1, 2023 /PRNewswire/ -- Leukemia, a type of blood cancer, affected around 2.3 million people around the world in 2015. Acute myeloid leukemia (AML)—a particularly aggressive disease—generally starts in the bone marrow, when stem cells cannot differentiate into white blood cells, which reduces the number of healthy blood cells in the body, leading to a very weak immune system, among other problems. Given the prevalence and implications of this disease, there has been a lot of research on the development and progression of leukemia. This has led to the discovery of a protein, stimulator of interferon genes (STING), which interacts with two other proteins—TANK-binding kinase 1 (TBK1) and signal transducer and activator of transcription 6 (STAT6)—to exert anti-cancer effects in blood cancers. Researchers have also observed that a particular gene—surfeit 4 (SURF4)—is highly expressed in leukemic cells, and its protein, SURF4, binds to STING. However, we are still unclear about how SURF4 affects the STING-TBK1-STAT6 axis, and what role it plays in leukemia. So, a team of researchers from Pusan National University, Republic of Korea set out to understand this. They were led by Professors Dongjun Lee and Yun Hak Kim, who explain the rather humanitarian motive for their research. "Children who suffer from AML relapses seldom survive. This makes studying the mechanisms of AML very important. Uncovering the effects of proteins like SURF4 may lead to new therapeutic strategies for AML, which hasn't happened in four decades". The team ran a series of experiments, the findings of which are detailed in a letter to the editor, published on 6 November 2022 in Cancer Communications.

Key Points: 
  • Given the prevalence and implications of this disease, there has been a lot of research on the development and progression of leukemia.
  • Researchers have also observed that a particular gene—surfeit 4 (SURF4)—is highly expressed in leukemic cells, and its protein, SURF4, binds to STING.
  • However, we are still unclear about how SURF4 affects the STING-TBK1-STAT6 axis, and what role it plays in leukemia.
  • So, a team of researchers from Pusan National University, Republic of Korea set out to understand this.

Albert Einstein College of Medicine Researchers Develop Promising New Cancer Therapy

Retrieved on: 
Tuesday, November 15, 2022
Albert Einstein College of Medicine, Technology, NK, Immunotherapy, Immunity, Student, YouTube, Microbiology, College, Melanoma, Ageing, Squamous cell carcinoma, University Hospital (Newark, New Jersey), AIDS, Diabetes, National, Lung, Attention, Lymphoma, PVR, Stomach, Partnership, Myeloid leukemia, Liver disease, Patient, Degenerative disease, Protein, Pembrolizumab, Paper, Pancreatic cancer, College of Medicine, Doctor of Philosophy, Montefiore, Microdeletion syndrome, Journal, Urology, Teaching hospital, Journal of Clinical Investigation, Multimedia, College of Medicine (UK), Head, Neuroscience, Neoplasm, JCI, Neck, TIGIT, Acute myeloid leukemia, Research, Patent, Albert Einstein, Large-cell lung carcinoma, Cancer research, Pharmaceutical industry, Vaccine, Cancer, Medicine, Facebook

Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement.

Key Points: 
  • Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement.
  • In a paper published online today in The Journal of Clinical Investigation (JCI), scientists at Albert Einstein College of Medicine describe findings that could bolster the effectiveness of immune-checkpoint therapy.
  • Rather than rally T cells against cancer, the Einstein research team used different human immune cells known as natural killer (NK) cellswith dramatic results.
  • About Albert Einstein College of Medicine Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation.

Glycostem and medac enter into license, manufacturing, supply and commercialization agreement for Glycostem's lead product - oNKord®

Retrieved on: 
Monday, August 1, 2022
Urology, MRD, MM, Natural killer T cell, Minimal residual disease, Hospital, Hematology, CEO, Degenerative disease, Patent, Therapy, GMP, Safety, Multiple myeloma, Cancer, Cell, Quality of life, Achievement, Clinical trial, Drug, Good manufacturing practice, Technology, AML, Medac, Patient, Acute myeloid leukemia, NK, Gesellschaft mit beschränkter Haftung, Good, Myeloid leukemia, Pharmaceutical industry, EU

Glycostem will receive an undisclosed upfront payment and through the manufacturing of oNKord a part of future revenues.

Key Points: 
  • Glycostem will receive an undisclosed upfront payment and through the manufacturing of oNKord a part of future revenues.
  • "This is our 2nd commercialization agreement following the deal with inno.N for Korea and Japan.
  • "Like Glycostem, medac is committed to developing novel therapies, especially in areas of unmet medical need such as AML and MM.
  • medac continually invests in its product development and manufacturing as well as logistic capacities to meet both patients' needs and the demands of healthcare professionals.

Glycostem and medac enter into license, manufacturing, supply and commercialization agreement for Glycostem's lead product - oNKord®

Retrieved on: 
Monday, August 1, 2022
Urology, MRD, MM, Natural killer T cell, Minimal residual disease, Hospital, Hematology, CEO, Degenerative disease, Patent, Therapy, GMP, Safety, Multiple myeloma, Cancer, Cell, Quality of life, Achievement, Clinical trial, Drug, Good manufacturing practice, Technology, AML, Medac, Patient, Acute myeloid leukemia, NK, Gesellschaft mit beschränkter Haftung, Good, Myeloid leukemia, Pharmaceutical industry, EU

Glycostem will receive an undisclosed upfront payment and through the manufacturing of oNKord a part of future revenues.

Key Points: 
  • Glycostem will receive an undisclosed upfront payment and through the manufacturing of oNKord a part of future revenues.
  • "This is our 2nd commercialization agreement following the deal with inno.N for Korea and Japan.
  • "Like Glycostem, medac is committed to developing novel therapies, especially in areas of unmet medical need such as AML and MM.
  • medac continually invests in its product development and manufacturing as well as logistic capacities to meet both patients' needs and the demands of healthcare professionals.